Cochrane for Clinicians
Putting Evidence into Practice
Does Metformin Increase the Risk of Fatal or Nonfatal Lactic Acidosis?
Am Fam Physician. 2010 Nov 1;82(9):1068-1070.
A 70-year-old woman with type 2 diabetes mellitus who is in otherwise good health is experiencing gradually increasing glucose levels. Her physician considers starting her on an oral diabetes agent, but is concerned that her age may put her at risk for adverse effects if she is treated with metformin (Glucophage).
Does metformin increase the risk of fatal or nonfatal lactic acidosis?
In patients without standard contraindications to metformin therapy, metformin does not increase the risk of lactic acidosis.1 (Strength of Recommendation = B, based on inconsistent or limited-quality patient-oriented evidence)
The first-line treatments recommended for type 2 diabetes are lifestyle changes and metformin, which is a biguanide antihyperglycemic agent.2 Demonstrated benefits of metformin include lower cardiovascular mortality than other oral diabetes medications3 and a reduced risk of death or myocardial infarction in overweight patients with type 2 diabetes.4 However, because an earlier biguanide, phenformin, was removed from the market after being linked to several cases of lactic acidosis, there have been concerns that metformin may predispose patients to lactic acidosis as well. In light of this, metformin is considered contraindicated in patients with chronic renal insufficiency, pulmonary disease, or hypoxic conditions; abnormal hepatic function; peripheral vascular disease; and in those older than 65 years. The use of metformin in patients with heart failure continues to be controversial.1
The authors of this Cochrane review found no cases of fatal or nonfatal lactic acidosis in 347 prospective trials and cohort studies with more than 70,490 patient-years of metformin use.1 Although the presence or absence of metformin contraindications among participants was not addressed in all studies, the authors note that 97 percent of the studies allowed for at least one metformin contraindication among included patients, and that 26 percent of all participants were estimated to be older than 65 years. Furthermore, one trial specifically studied 393 patients with at least one contraindication to metformin and found no cases of lactic acidosis. All patients in this trial had serum creatinine values ranging from 1.5 to 2.5 mg per dL (132.60 to 221.00 μmol per L).5
Because metformin has demonstrated benefits for patient-oriented outcomes in the treatment of type 2 diabetes, the absence of any cases of lactic acidosis among all patients included in the reviewed studies is reassuring regarding the safety of metformin in general. Considering that there was no standardized reporting across the studies of metformin use in the presence of contraindications, definitive conclusions about the safety of metformin in the presence of contraindications are not possible.
Nevertheless, the review authors suggest that concerns for lactic acidosis with metformin use may be overstated for the following three reasons. First, despite chemical similarities, phenformin and metformin have different mechanisms of action. Whereas phenformin can impair hepatic oxidative phosphorylation and increase anaerobic lactate production, metformin inhibits hepatic gluconeogenesis without affecting lactate turnover. Second, the case reports of lactic acidosis with metformin use all occurred in patients with other underlying conditions that could independently predispose to lactic acidosis. Third, diabetes alone is a predisposing factor for the development of lactic acidosis; thus, cases of lactic acidosis in patients taking metformin may have been caused by having diabetes rather than by taking metformin.1
The reality of current clinical practice is that 54 to 73 percent of patients taking metformin have at least one standard contraindication to its use, and the review authors note that strict adherence to recommended contraindication guidelines would reduce the number of patients with diabetes being treated with metformin by about one half.1 Because metformin has clear patient-oriented benefits and no demonstrable risk of lactic acidosis in low-risk patients, it should remain a first-line treatment option for patients with type 2 diabetes. Patients with contraindications to metformin may also be those who potentially stand to benefit the most from metformin therapy. Although this Cochrane review does not specifically address the safety of metformin in the presence of contraindications, it suggests that even in the presence of one contraindication, the benefits of metformin use may outweigh the risks.
Background: Metformin is an oral antihyperglycemic agent that has been shown to reduce total mortality compared with other antihyperglycemic agents in the treatment of type 2 diabetes mellitus. Metformin, however, is thought to increase the risk of lactic acidosis, and has been considered to be contraindicated in many chronic hypoxemic conditions that may be associated with lactic acidosis, such as cardiovascular, renal, hepatic, and pulmonary diseases, and advancing age.
Objectives: To assess the incidence of fatal and nonfatal lactic acidosis and to evaluate blood lactate levels for those on metformin treatment compared with placebo or non-metformin therapies.
Search Strategy: A comprehensive search was performed of electronic databases to identify studies of metformin treatment. The search was augmented by scanning references of identified articles, and by contacting principal investigators.
Selection Criteria: Prospective trials and observational cohort studies in patients with type 2 diabetes of at least one month's duration were included if they evaluated metformin, alone or in combination with other treatments, compared with placebo or any other glucose-lowering therapy.
Data Collection and Analysis: The incidence of fatal and nonfatal lactic acidosis was recorded as cases per patient-years for metformin treatment and for non-metformin treatments. The upper limit for the true incidence of cases was calculated using Poisson statistics. In a second analysis, lactate levels were measured as a net change from baseline or as mean treatment values (basal and stimulated by food or exercise) for treatment and comparison groups. The pooled results were recorded as a weighted mean difference in mmol per L, using the fixed-effect model for continuous data.
Main Results: Pooled data from 347 comparative trials and cohort studies revealed no cases of fatal or nonfatal lactic acidosis in 70,490 patient-years of metformin use or in 55,451 patient-years in the non-metformin group. Using Poisson statistics, the upper limit for the true incidence of lactic acidosis per 100,000 patient-years was 4.3 cases in the metformin group and 5.4 cases in the non-metformin group. There was no difference in lactate levels, either as mean treatment levels or as a net change from baseline, for metformin compared with non-metformin therapies.
Authors' Conclusions: There is no evidence from prospective comparative trials or from observational cohort studies that metformin is associated with an increased risk of lactic acidosis or with increased levels of lactate compared with other antihyperglycemic treatments.
These summaries have been derived from Cochrane reviews published in the Cochrane Database of Systematic Reviews in the Cochrane Library. Their content has, as far as possible, been checked with the authors of the original reviews, but the summaries should not be regarded as an official product of the Cochrane Collaboration; minor editing changes have been made to the text (http://www.cochrane.org).
REFERENCESshow all references
1. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(1):CD002967....
2. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203.
3. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–2080.
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet. 1998;352(9139):1558]. Lancet. 1998;352(9131):854–865.
5. Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med. 2002;13(7):428.
The Cochrane Abstract is a summary of a review from the Cochrane Library. It is accompanied by an interpretation that will help clinicians put evidence into practice. Dr. Cayley presents a clinical scenario and question based on the Cochrane Abstract, followed by an evidence-based answer and a critique of the review. The practice recommendations in this activity are available at http://www.cochrane.org/reviews/en/ab002967.html.
The series coordinator for AFP is Clarissa Kripke, MD, Department of Family and Community Medicine, University of California, San Francisco.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Sep 15, 2018
Access the latest issue of American Family Physician